Eli Lilly Has a New Drug That Could Push the Stock Higher
Lilly's main competitor is Leqembi, from Biogen and Eisai, which gained FDA approval in 2023 and works by reducing amyloid plaques in the brain. Eisai, the Japanese firm that makes the drug, predicts it will bring in $2 billion in revenue by March 2027.